Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
The chart shows the growth of an initial investment of $10,000 in Bruker Corporation, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Bruker Corporation (BRKR) has returned -22.10% so far this year and 3.40% over the past 12 months. Looking at the last ten years, BRKR has achieved an annualized return of 2.26%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
BRKR
1M-2.80%
6M-0.35%
YTD-22.10%
1Y3.40%
5Y-11.78%
10Y2.26%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Bruker Corporation (BRKR) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
-6.15%
-9.44%
-9.53%
0.35%
2025
-1.56%
-16.51%
-11.74%
-4.14%
-8.32%
12.66%
-6.13%
-10.58%
-3.76%
19.67%
29.32%
-3.11%
2024
-1.64%
20.58%
8.21%
-17.00%
-16.03%
-2.99%
6.81%
-1.16%
3.48%
-17.80%
-0.50%
2.11%
2023
1.39%
-1.85%
14.39%
0.58%
-12.73%
6.85%
-7.29%
-5.46%
-5.51%
-8.20%
14.60%
13.33%
2022
-20.42%
4.64%
-8.37%
-11.36%
9.23%
-0.51%
9.89%
-18.26%
-4.69%
15.05%
8.20%
0.87%
2021
6.30%
4.31%
3.86%
6.53%
0.64%
8.31%
8.35%
6.49%
-11.58%
2.50%
0.97%
3.37%
2020
-4.37%
-12.44%
-18.30%
18.11%
12.94%
-5.72%
10.09%
-6.25%
-5.36%
7.56%
18.08%
6.14%
2019
19.29%
8.52%
-0.10%
-0.41%
8.07%
19.81%
-5.62%
-9.80%
2.54%
1.30%
2.32%
-1.03%
2018
3.22%
-13.39%
-2.38%
-0.64%
2.64%
-4.25%
12.19%
10.19%
-5.11%
-6.37%
5.58%
-11.32%
2017
11.93%
1.77%
-4.27%
4.23%
10.70%
6.11%
-1.00%
1.32%
2.34%
5.19%
11.97%
-2.47%
2016
1.43%
-7.27%
-13.99%
9.20%
-10.16%
1.52%
-9.26%
10.80%
-6.49%
Performance Indicators
The charts below present risk-adjusted performance metrics for Bruker Corporation (BRKR) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of BRKR compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Bruker Corporation volatility is 2.83%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Liabilities And Equity (USD)
6.24B
4.25B
3.61B
3.65B
3.05B
2.77B
2.13B
1.95B
1.81B
1.73B
1.86B
1.99B
1.86B
1.71B
Temporary Equity (USD)
36.80M
18.70M
6.10M
200.00K
-
21.10M
22.60M
-
-
-
-
-
-
-
Equity Attributable To Parent (USD)
2.46B
1.38B
1.11B
1.07B
961.20M
906.80M
896.60M
725.40M
686.40M
726.10M
765.90M
846.10M
706.60M
621.50M
Equity Attributable To Noncontrolling Interest (USD)
Markets traded cautiously on Tuesday despite benign inflation data (CPI at 2.7% YoY, core CPI at 2.6%) that supported Fed rate cut expectations. Silver surged 4.5% to $89/oz amid supply concerns. Major indices remained flat with the S&P 500 near record highs. Earnings results were mixed: JPMorgan fell 3% on weak investment banking fees, Delta slid 4% on soft guidance, while Moderna rallied 14% on bullish forecasts. Intel and AMD gained on analyst upgrades. Energy stocks outperformed as crude rose 2.7% to $61/barrel.
Benzinga•Piero Cingari
AI Insight
Stock fell 6.6%, ranking among the top 5 Russell 1000 losers
Lane Generational, a Massachusetts-based investment advisor, completely sold its $3.6 million stake in Bruker during Q3 2025, exiting all 87,607 shares amid the company's challenging market performance.
The Motley Fool•Jonathan Ponciano
AI Insight
Stock has fallen 32% in past 12 months, missed earnings expectations, experienced weaker academic and research spending, and remains below 2021 highs
The global molecular spectroscopy market is projected to grow from USD 6.97 billion in 2024 to USD 9.04 billion by 2034, driven by expanding healthcare applications, research growth, and technological advancements in drug discovery and diagnostics.
GlobeNewswire Inc.•Towards Healthcare
AI Insight
Actively expanding capabilities through strategic investments and acquisitions, such as acquiring Bridge12's Electron Paramagnetic Resonance business and investing in RECIPE Chemicals + Instruments
The next-generation proteomics market is projected to expand rapidly between 2025-2034, driven by technological advancements, rising chronic disease prevalence, and increasing demand for personalized medicine across pharmaceutical, biotechnology, and diagnostic sectors.
GlobeNewswire Inc.•Towards Healthcare
AI Insight
Mentioned as a key market player with no specific recent developments highlighted
The global PFAS testing market is projected to grow from $306.60 million in 2024 to $1.25 billion by 2037, driven by increasing environmental and health regulations around 'forever chemicals' across North America, Europe, and Asia.
GlobeNewswire Inc.•Researchandmarkets.Com
AI Insight
Mentioned as a market participant with potential opportunities in PFAS testing technologies
Biognosys has expanded its contract research services to include quantitative metabolomics and lipidomics, leveraging biocrates MxP® Quant 1000 kit and Bruker's mass spectrometry platforms to provide comprehensive multiomics research capabilities.
GlobeNewswire Inc.•Kristina Beeler
AI Insight
Mentioned as technology provider without significant strategic implications
Medical device company Bruker announced a $600 million mandatory convertible preferred stock offering to retire debt, causing an 11.68% stock price decline on Wednesday.
The Motley Fool•Eric Volkman
AI Insight
Stock price dropped nearly 12% following the announcement of a significant stock offering, raising investor concerns about financial health and potential share dilution
The Atomic Spectroscopy Market is projected to grow from USD 1.57 Billion in 2024 to USD 2.37 Billion by 2032, with a CAGR of 5.28%, driven by increasing demand for precise elemental analysis in pharmaceuticals, environmental monitoring, and food safety.
GlobeNewswire Inc.•Sns Insider
AI Insight
Highlighted for recent technological developments and innovation in analytical instrumentation
Bruker reported Q2 2025 earnings with GAAP revenue of $797.4 million, missing analyst estimates and declining 0.4% year-over-year. The company experienced softer demand in U.S. academic and biopharma markets, leading to margin compression and reduced full-year guidance.
The Motley Fool•Jesterai
AI Insight
Missed revenue and earnings estimates, declined revenue, reduced full-year guidance, negative performance across most segments, and announced cost-cutting measures indicating challenging business conditions
Wall Street indices extended record highs on strong earnings and investor confidence, with gold prices surging to $3,400 amid dollar weakness and speculation about Federal Reserve leadership.
Benzinga•Piero Cingari
AI Insight
Stock fell 14% after issuing preliminary Q2 revenue guidance below Wall Street estimates
